On November 6, 2025, Mr. Yang Xiaobo, Chairman of Hainan Medical University Asset Management Co., Ltd., led a delegation to visit Zhejiang Tianyuan Biotechnology Co., Ltd. for an inspection tour. They were warmly received by Mr. Huang Bisheng, Chairman of the Group, and Mr. Jiao Mingming, General Manager of Tianyuan Biotech, along with their teams.

      Chairman Yang Xiaobo and his delegation first visited Zhejiang Tianhao Holding Group for an exchange session. Chairman Huang Bisheng provided a detailed overview of the Group’s development journey, highlighting its expansion from initial engineering consulting services into diverse sectors including biomedicine and rail transit equipment, showcasing the Group’s diversified industrial layout and robust development capabilities. Ms. Zhu Youwu, Chief Administrative Officer of the Group, elaborated on the Group’s business portfolio, underscoring its comprehensive competitiveness across multiple fields.

      Subsequently, Chairman Yang Xiaobo and his delegation proceeded to Zhejiang Tianyuan Biotechnology Co., Ltd., where they toured the company’s Science and Technology Exhibition Hall and laboratories, gaining an in-depth understanding of Tianyuan Biotech’s technological advantages and development history in the biomedical field.

      During the subsequent exchange meeting, Chairman Yang Xiaobo expressed high recognition of the strengths of both Tianhao Holding Group and Tianyuan Biotech. General Manager Jiao Mingming presented a detailed introduction to the company’s advantages in cell culture and iPSC (induced Pluripotent Stem Cell) technology, emphasizing that through continuous technological innovation and R&D investment, the company is committed to providing safer and more effective health service solutions for patients.

      Chairman Yang Xiaobo noted that as a national "pilot zone" for biomedicine, Hainan possesses unique advantages in policy support and innovation environment. This visit has laid a solid foundation for future cooperation between the two parties. He expressed hope for deep collaboration with Tianyuan Biotech in areas such as cellular medicine R&D, clinical application translation, and industrialization, aiming to jointly advance the development of the biomedical industry and inject new vitality into Hainan’s greater health sector.

      Chairman Huang Bisheng stated that Tianyuan Biotech will continue to uphold the philosophy of innovation-driven development, fully leverage its technological advantages and industrial experience, and actively expand its business presence in Hainan. The company looks forward to comprehensive cooperation with Hainan Medical University Asset Management Co., Ltd. in biomedical R&D, clinical research, and talent cultivation, jointly exploring innovative applications in Hainan, and making positive contributions to enhancing the nation's biomedical standards and promoting the development of the greater health industry.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Cancer Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.